Anti-Human Siglec-2/CD22 Recombinant Antibody (RFB-4), APC (HB011337)

Name: Anti-Human Siglec-2/CD22 Recombinant Antibody (RFB-4), APC
Brand: abinScience
SKU: HB011337
Price: 290 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50T
100T

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HB011337
Reactivité des espèces	Human
Applications	ELISA, FCM
Espèce hôte	Mouse
Clonalité	Monoclonal
Isotype	IgG1, kappa
ID de clone	RFB-4
Conjugaison	APC
Applications testées	FCM
Cible	B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
Niveau d'endotoxines	Please contact with the lab for this information.
Pureté	>90% as determined by SDS-PAGE.
Produits associés	Mouse IgG1, kappa Recombinant Isotype Control Antibody (MOPC-21), APC
Numéro d'accès	P20273
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Store at 4°C for 12 months. Protect from light. Do not freeze.
Contexte	B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366
Reférences	1. Kreitman RJ, et al. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer. 1999 Mar 31;81(1):148-55. [HB011337] 2. Mansfield E, et al. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;90(5):2020-2026. [HB011337]
Note	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.

Images

Flow CytoMetry

Flow-cytometry using APC anti-human CD22 antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD22 monoclonal antibody (Catalog: HB011337, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

Reférences

Fiche technique